Matthew Baggott to Male
This is a "connection" page, showing publications Matthew Baggott has written about Male.
Connection Strength
0.238
-
Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. J Psychoactive Drugs. 2019 Apr-Jun; 51(2):108-117.
Score: 0.033
-
Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol. 2016 Apr; 30(4):378-87.
Score: 0.026
-
Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol. 2015 Jun; 29(6):669-77.
Score: 0.025
-
Psychopharmacology of theobromine in healthy volunteers. Psychopharmacology (Berl). 2013 Jul; 228(1):109-18.
Score: 0.021
-
Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. PLoS One. 2010 Dec 02; 5(12):e14074.
Score: 0.018
-
Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend. 2011 Mar 01; 114(1):61-7.
Score: 0.018
-
Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend. 2010 Oct 01; 111(3):250-6.
Score: 0.018
-
Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine. J Pharmacol Exp Ther. 2024 Sep 18; 391(1):22-29.
Score: 0.012
-
Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing. Neuropsychopharmacology. 2020 04; 45(5):823-832.
Score: 0.009
-
Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther. 1996 Jul; 60(1):105-14.
Score: 0.007
-
MDMA effects consistent across laboratories. Psychopharmacology (Berl). 2014 Oct; 231(19):3899-905.
Score: 0.006
-
Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention. Exp Clin Psychopharmacol. 2013 Dec; 21(6):475-81.
Score: 0.006
-
Ketamine is associated with lower urinary tract signs and symptoms. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):189-94.
Score: 0.005
-
A method to quantify illicit intake of drugs from urine: methamphetamine. J Pharmacol Exp Ther. 2011 Jul; 338(1):31-6.
Score: 0.005
-
A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011 Feb; 89(2):276-82.
Score: 0.005
-
Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology (Berl). 2011 Apr; 214(4):933-9.
Score: 0.005
-
An examination of drug craving over time in abstinent methamphetamine users. Am J Addict. 2010 Nov-Dec; 19(6):510-4.
Score: 0.004
-
Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose. Ther Drug Monit. 2010 Aug; 32(4):504-7.
Score: 0.004
-
The effects of inhaled L-methamphetamine on athletic performance while riding a stationary bike: a randomised placebo-controlled trial. Br J Sports Med. 2009 Oct; 43(11):832-5.
Score: 0.004
-
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002 Aug; 162(4):396-405.
Score: 0.003
-
Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000 Dec 19; 133(12):969-73.
Score: 0.002
-
Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl). 1999 Jan; 141(1):37-46.
Score: 0.002
-
A high-dose methamphetamine regimen results in long-lasting deficits on performance of a reaction-time task. Brain Res. 1993 Nov 12; 627(2):254-60.
Score: 0.001